Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2017 Oct 18;6(3):1078–1080. doi: 10.1016/j.jaip.2017.09.014

Table 1.

Demographic and clinical data for CRS and control subjects. Abbreviations: AERD (Aspirin Exacerbated Respiratory Disease), AFS (Allergic Fungal Sinusitis), AR (Allergic Rhinitis), ASA Sens. (Aspirin Sensitivity), DM (Diabetes Mellitus), GERD (Gastroesophageal Reflux Disease), OSA (Obstructive Sleep Apnea), FESS (Functional Endoscopic Sinus Surgery).

CRS Control P
Total Enrollment 328 287

Female – N (%) 129 (39%) 166 (58%) <0.001
Race – N (%) 0.787
 White 289 (88.1%) 249 (87.1%)
 Non-White 39 (11.9%) 38 (12.9%)
Ethnicity – N (%) 0.003
 Hispanic 3 (1%) 15 (5.2%) -
 Non-Hispanic 325 (99.1%) 272 (94.8%) -
Smoker – N (%) <0.001
 Never 197 (60.1%) 236 (82.2%)
 Ever 131 (39.9%) 51 (17.8%)
Comorbidities – N (%)
 Asthma 162 (49.4%) 41 (14.4%) <0.001
 AERD 42 (12.8%) - -
 AFS 14 (4.3%) - -
 AR 248 (75.6%) - -
 ASA Sens. 46 (14.0%) - -
 DM 24 (7.3%) - -
 GERD 111 (33.8%) - -
 Hypertension 92 (28.0%) - -
 OSA 45 (13.7%) - -
Nasal Polyps – N (%) 186 (56.7%) - -
Prior FESS – N (%)
 Primary 131 (39.9%) - -
 Revision 197 (60.1%) - -
Mean (SD) Mean (SD)
Age at Enrollment 48.6 (15.3) 40.4 (15.4) <0.001
SNOT-22 46.6 (22.2) 10.6 (12.2) <0.001
BMI 28.0 (5.3) -
Lund-Mackay CT 12.3 (6.0) -